• A Safety and Tolerability Study of Mexiletine in Patients with Sporadic Amyotrophic Lateral Sclerosis (SALS)
Massachusetts General Hospital is seeking individuals to participate in a research study enrolling under the direction of Dr. Nazem Atassi.

The purpose of the research study is to determine whether mexiletine is safe and tolerable for patients with Sporadic Amyotrophic Lateral Sclerosis (SALS). While taking the study drug, participants will be asked to complete several tests and a questionnaire. From this study, the researchers hope to learn more about ALS and its treatment.

Participants must be at least 18 years of age. Participants should be located close to the study site and be able to follow study tasks. If interested, please contact one of our coordinators, Owen O’Connor, at 617-726-5059 or by e-mail at ojoconnor@partners.org. You may also contact the Coordination Center via the Northeast ALS Consortium (NEALS) for more information about this study at mghneuroclinicaltrialsunit@partners.org or toll free at 1-877-458-0631.
Institution  –  MGH - Massachusetts General Hospital, Boston, MA
Principal Investigator  – Nazem Atassi, MD
  
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name  – Owen O'Connor
Phone  – 617-726-5059